{"name":"Lilac Therapeutics, Inc.","slug":"lilac-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxNRVFtQmZLYV9TQzEwb1ViWk1QbU5NX3l1XzJKTHFJQ180RlBuY0lqcE14QmxOcVVMWF9SRFFZVVdmMVU0NFZEcUIzLV90eWw1c2xsTXRpZ1U3ZVBqTDdWcms5V2p3LTJuUVZhSUdmd0gxMkJja3dNZlcxMHZ4UFFxZWQ3dWwzRW9WcGlyQWtncXE?oc=5","date":"2025-09-25","type":"pipeline","source":"Brown University","summary":"Brown researchers bring bold ideas to life at Innovation@Brown Showcase - Brown University","headline":"Brown researchers bring bold ideas to life at Innovation@Brown Showcase","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPcmd1bXAzaUlucmZ3LUdwZXZNbW1ROU9TWXNaNG9EaktBQzhJUllCQXZMcFNweU9KRDQwMXpHOUgyVVRVOS01aUlKdWdDQUduOUgyWnB1WlpfZXlmbU4yLURWMFJSbFZoUGFUNUZUN2Q0ZWd0U0ZtSWxndkhvNlpYd2g1M3ZkQm5QVWdnYzR2SlpCdWdRN2lmQy1IRklkV0ZvWjluOU1rc0lVOUk?oc=5","date":"2025-01-24","type":"trial","source":"dicardiology.com","summary":"Study Shows Abelacimab Significantly Reduced Bleeding vs. Standard DOAC - dicardiology.com","headline":"Study Shows Abelacimab Significantly Reduced Bleeding vs. Standard DOAC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOUEl6ZnZDbFp4UEY1V0NhaU1MZ01tR0JVeUFuOFhMR3FRcEp1S0ItQzhjbXVXSjQ3djE3N3dJbEY5OGh4VVNhNGx0NnYtQ3dlTTh0Ym1Ia0VZUFUxWFlPRXY4VHdPWEUxLVIyRnBGZXBsTEo4U0ZoQmRRWU5xWnlMOUs2aUhsYWFuY0ZMb0duc3UtcTRXOUVaZDhpTjRhdVJEZGhiWXpVZVpUa3pTUGxZcmFiSjl2LTFLRlBHMQ?oc=5","date":"2023-09-26","type":"trial","source":"dicardiology.com","summary":"Study Confirming Overwhelming Reduction in Bleeding of the Dual-Acting Factor XI/XIa Inhibitor Abelacimab as Compared to Rivaroxaban Selected as Late-Breaker Oral Presentation at the American Heart As","headline":"Study Confirming Overwhelming Reduction in Bleeding of the Dual-Acting Factor XI/XIa Inhibitor Abelacimab as Compared to","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxNRkw4c3BISmg4MzdJTmF6SzFhS2xyT1pSUVVaOGRIX0x2UXJmRTJHTEdZSWd3ZDgwaS12endzdUo1OVdnMzdWSEdISDlGc1hveGg4TDZyLU9mNmZxTHptQ2Z1S1RKM2NJQjYwZFdfczljSXotQWtnajUzelFVVDNKb1ZIcw?oc=5","date":"2020-11-15","type":"pipeline","source":"C&EN","summary":"C&EN’s 2020 10 Start-Ups to Watch - C&EN","headline":"C&EN’s 2020 10 Start-Ups to Watch - C&EN","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}